FastWave Medical has added four international patents to its intellectual property (IP) portfolio, the company revealed recently. This brings FastWave’s total to 13 patents worldwide, including nine in the USA.
The new patents cover both of FastWave’s intravascular lithotripsy (IVL) platforms— Artero, the company’s electric IVL system for peripheral arterial disease (PAD), and Sola, its laser-based IVL (L-IVL) system for coronary artery disease (CAD)—with two issued in Australia and two in Japan.
As physicians increasingly turn to IVL to treat calcific artery disease, the category has become one of the most closely watched areas in cardiovascular medical devices. FastWave states that it is advancing the next generation of IVL technology to address certain limitations assocatied with first-generation devices across both peripheral and coronary applications.
“Calcified arterial disease remains one of the most difficult challenges in interventional medicine, particularly when calcium limits device delivery, lesion expansion, or procedural efficiency,” said Miguel Montero-Baker (HOPE Amputation Prevention Center, Houston, USA). “As IVL becomes more widely adopted, physicians will continue to look for technologies that can make calcium modification fast, predictable, and easy to integrate into real-world procedures.”
Last year, FastWave completed a 30-patient first-in-human study of its L-IVL coronary platform, following an earlier first-in-human study of its electric peripheral IVL platform. The company shares that both are on track to advance into IDE trials throughout 2026 and 2027.
